CMV infection/disease post-transplant
Infectious disease · 2023–2024
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| maribavir Acute treatment of post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies. | Nov 2024 | Recommended with restriction | input received |
| maribavir Acute treatment of adults with post-transplant cytomegalovirus (CMV) infection or CMV disease resistant, refractory or intolerant to one or more prior… | Nov 2023 | Not recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.